Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR6.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR3.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR1.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR2.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR7.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR8.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR9.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR4.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR13.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR10.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR11.htm
XML - IDEA: XBRL DOCUMENT - Accelerate Diagnostics, IncR12.htm
EX-31.2 - CERTIFICATION - Accelerate Diagnostics, Incaccelr84302012exh312.htm
EX-32.1 - CERTIFICATION - Accelerate Diagnostics, Incaccelr84302012exh321.htm
EX-31.1 - CERTIFICATION - Accelerate Diagnostics, Incaccelr84302012exh311.htm
10-Q - FORM 10-Q - Accelerate Diagnostics, Incaccelr84302012.htm
v2.4.0.6
Condensed Statements of Cash Flows (USD $)
9 Months Ended
Apr. 30, 2012
Apr. 30, 2011
Cash flows from operating activities:    
Net Income (loss) $ (1,141,846) $ (83,103)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:    
Depreciation 1,546 1,797
Amortization 192,845 189,860
Fair value of stock options granted for services 347,614 18,677
Unrealized holding (gain) loss on investments (29,017) (36,907)
Reinvested earnings-interest and dividends (5,719) (4,383)
(Increase) decrease in assets:    
Accounts receivable (1,828) (18,642)
Inventory 0 2,072
Prepaid expense and other (4,204) (12,770)
Increase (decrease) in liabilities:    
Accounts payable 15,030 62,651
Accrued liabilities 19,271 14,489
Deferred revenue 83,657 (20,225)
Deferred compensation 90,986 97,540
Net cash provided (used in) operating activities (431,665) 211,056
Cash flows from financing activities:    
Sale of common stock 0 0
Cash flows from investing activities:    
Purchases of equipment and patents (56,196) (47,068)
Contribution to deferred compensation trust (75,000) (75,000)
Net cash used in investing activities (131,196) (122,068)
Increase (Decrease) in cash and cash equivalents (562,861) 88,988
Beginning balance 775,856 283,273
Ending balance $ 212,995 $ 372,261